MORRISTOWN, N.J.--(BUSINESS WIRE)--Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company, today announced financial results for the first quarter ended March 31, 2015.
Highlights of and subsequent to the quarter:
•Acquired the Zohydro ER franchise from Zogenix, Inc. for $80.9 million in upfront cash, approximately 1.7 million shares of Pernix common stock, and potential regulatory and commercial milestone payments;
Help employers find you! Check out all the jobs and post your resume.
